AbbVie Inc.
At today's price, AbbVie Inc. (ABBV) is priced for +17.4% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
- The counterintuitive number is AbbVie's negative book equity, which trips distress flags in mechanical screens. It is not distress. It is the accounting footprint of large acquisitions and years of dividends and buybacks on a company that generates about $20 billion of free cash flow. The balance sheet looks alarming and the cash generation is anything but. - The post-Humira transition is essentially complete and working. In Q1 2026 Skyrizi reached $4.48 billion (up about 31%) and Rinvoq $2.12
Is ABBV overvalued? See what's priced in →
3,989 institutional managers reported holding ABBV in 13F filings for the quarter ended 2026-03-31. Together they hold about 70% of the company; the top 10 hold 35%. 128 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 23.4M shares were sold short as of the 2026-06-15 count, about 1% of shares outstanding (4.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ABBV's share count is about flat over the past five years ($7.78B of repurchases, offset by issuance). It pays a dividend, and has paid one every year in our records (13 and counting), raised 12 years straight; the current rate is $6.65 a share annually. Cash returned over the past three years: $31.02B in dividends and $4.19B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at ABBV over the trailing three years. Absence is a fact about the company, not a signal. 26 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ABBV's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-08 | +6.3% | -0.5% |
| 2023-11-07 | -4.3% | +14.2% |
| 2024-02-21 | -1.3% | -4.2% |
| 2024-05-04 | -4.6% | +2.1% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ABBV's latest 8-K filings: 2026-07-06 (items 2.02, 9.01); 2026-06-22 (items 7.01, 9.01); 2026-05-12 (items 5.07); 2026-04-29 (items 2.02, 9.01); 2026-04-03 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: July 3, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.